Joint (JYNT) Revenue & Revenue Breakdown


OverviewForecastOwnershipFinancialsChartTranscripts

Joint Revenue Highlights


Latest Revenue (Y)

$54.90M

Latest Revenue (Q)

$15.18M

Main Segment (Y)

Royalty

Joint Revenue by Period


Joint Revenue by Year

DateRevenueChange
2025-12-31$54.90M5.24%
2024-12-31$52.16M11.04%
2023-12-31$46.98M-53.60%
2022-12-31$101.25M26.55%
2021-12-31$80.01M36.34%
2020-12-31$58.68M21.12%
2019-12-31$48.45M52.41%
2018-12-31$31.79M26.33%
2017-12-31$25.16M22.61%
2016-12-31$20.52M48.34%
2015-12-31$13.84M94.41%
2014-12-31$7.12M19.45%
2013-12-31$5.96M113.94%
2012-12-31$2.78M-

Joint generated $54.90M in revenue during NA 2025, up 5.24% compared to the previous quarter, and up 93.55% compared to the same period a year ago.

Joint Revenue by Quarter

DateRevenueChange
2026-06-30$15.18M2.44%
2026-03-31$14.82M-2.29%
2025-12-31$15.17M13.35%
2025-09-30$13.38M0.83%
2025-06-30$13.27M1.47%
2025-03-31$13.08M-134.16%
2024-12-31$-38.28M-226.78%
2024-09-30$30.20M139.48%
2024-06-30$12.61M3.49%
2024-03-31$12.18M-60.20%
2023-12-31$30.61M3.87%
2023-09-30$29.47M0.57%
2023-06-30$29.31M3.56%
2023-03-31$28.30M1.76%
2022-12-31$27.81M5.15%
2022-09-30$26.45M6.28%
2022-06-30$24.89M11.92%
2022-03-31$22.24M0.61%
2021-12-31$22.10M5.29%
2021-09-30$20.99M3.82%
2021-06-30$20.22M15.22%
2021-03-31$17.55M2.99%
2020-12-31$17.04M10.56%
2020-09-30$15.41M22.41%
2020-06-30$12.59M-7.73%
2020-03-31$13.64M-1.66%
2019-12-31$13.88M9.03%
2019-09-30$12.73M13.93%
2019-06-30$11.17M4.59%
2019-03-31$10.68M17.72%
2018-12-31$9.07M12.52%
2018-09-30$8.06M6.69%
2018-06-30$7.56M6.47%
2018-03-31$7.10M2.43%
2017-12-31$6.93M5.86%
2017-09-30$6.55M8.83%
2017-06-30$6.01M6.01%
2017-03-31$5.67M-1.85%
2016-12-31$5.78M5.04%
2016-09-30$5.50M10.65%
2016-06-30$4.97M16.62%
2016-03-31$4.27M13.35%
2015-12-31$3.76M-9.07%
2015-09-30$4.14M20.76%
2015-06-30$3.43M36.64%
2015-03-31$2.51M22.02%
2014-12-31$2.06M13.15%
2014-09-30$1.82M4.89%
2014-06-30$1.73M14.48%
2014-03-31$1.51M-8.45%
2013-12-31$1.65M12.20%
2013-09-30$1.47M-

Joint generated $15.18M in revenue during Q2 2026, up 2.44% compared to the previous quarter, and up 116.09% compared to the same period a year ago.

Joint Revenue Breakdown


Joint Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 25Dec 24Dec 23Dec 22Dec 21
Royalty$33.20M$32.14M$29.16M$26.19M$22.06M
Technology Service$6.04M$5.69M$5.09M$4.29M$3.38M
Product and Service, Other$1.83M$1.89M$1.53M$1.45M$1.26M
Franchise$3.37M$3.00M$2.88M$2.44M$2.66M
Advertising$10.45M$9.18M$8.32M$7.46M$6.30M
Revenues and Management Fees from Company Clinics--$70.72M$59.42M$44.35M
Regional Developer Fees---$659.10K$848.64K

Joint's latest annual revenue breakdown by segment (product or service), as of Dec 25: Royalty (60.49%), Advertising (19.04%), Technology Service (11.00%), Franchise (6.14%), and Product and Service, Other (3.34%).

Quarterly Revenue by Product

Product/ServiceJun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21
Product and Service, Other$840.61K$460.89K$449.42K$418.81K$554.69K$408.62K$1.09M$407.13K$387.99K$409.04K$342.14K$384.96K$390.00K$392.72K$375.31K$370.56K$312.14K$372.58K$316.06K$310.07K
Royalty$8.33M$8.03M$8.89M$8.11M$8.13M$8.07M$16.69M$7.87M$7.59M$7.98M$7.14M$7.17M$6.87M$7.17M$6.60M$6.41M$6.01M$6.25M$5.71M$5.33M
Franchise$750.59K$1.15M$810.09K$964.80K$768.10K$828.52K$344.72K$2.00M$655.87K$703.07K$754.03K$671.37K$754.42K$471.07K$642.40K$686.89K$640.97K$691.42K$648.60K$623.65K
Advertising$3.72M$3.65M$3.47M$2.34M$2.33M$2.31M$4.77M$2.25M$2.17M$2.28M$2.05M$2.04M$1.95M$2.04M$1.88M$1.83M$1.71M$1.78M$1.63M$1.52M
Technology Service$1.55M$1.53M$1.55M$1.55M$1.48M$1.46M$2.87M$1.43M$1.39M$1.34M$1.30M$1.23M$1.21M$1.12M$1.11M$1.10M$957.00K$996.31K$840.97K$786.04K
Revenues and Management Fees from Company Clinics-------$17.54M$17.54M$17.91M$17.88M$17.80M$17.13M$16.49M$15.84M$14.49M$12.61M$11.81M$11.63M$11.43M
Regional Developer Fees------------$149.48K$134.18K$153.18K$169.95K$201.79K$206.60K$209.65K$214.43K

Joint's latest quarterly revenue breakdown by segment (product or service), as of Jun 26: Royalty (54.85%), Advertising (24.48%), Technology Service (10.19%), Product and Service, Other (5.54%), and Franchise (4.94%).

Joint Revenue Breakdown by Country

Quarterly Revenue by Country

CountryMar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Dec 18Sep 18Jun 18
Advertising$1.95M$2.04M$1.88M$1.83M$1.71M$1.78M$1.63M$1.52M$1.37M$1.33M$1.19M$930.79K$1.06M$1.09M$978.21K$927.80K$736.99K$687.75K--
Regional Developer Fees$149.48K$134.18K$153.18K$169.95K$201.79K$206.60K$209.65K$214.43K$217.96K$232.83K$222.91K$213.42K$207.64K$209.23K$210.23K$200.52K$184.29K$142.65K$137.41K-
Royalty$6.87M$7.17M$6.60M$6.41M$6.01M$6.25M$5.71M$5.33M$4.77M$4.73M$4.17M$3.27M$3.72M$3.82M$3.45M$3.26M$2.59M$2.42M--
Franchise$754.42K$471.07K$642.40K$686.89K$640.97K$691.42K$648.60K$623.65K$695.43K$544.95K$519.13K$523.96K$512.75K$385.87K$541.34K$447.27K$433.04K$457.52K$449.14K-
Product and Service, Other$390.00K$392.72K$375.31K$370.56K$312.14K$372.58K$316.06K$310.07K$259.20K$255.66K$218.27K$164.95K$208.22K$203.32K$205.40K$176.45K$137.78K$124.74K--
Revenues and Management Fees from Company Clinics$17.13M$16.49M$15.84M$14.49M$12.61M$11.81M$11.63M$11.43M$9.47M$9.22M$8.40M$6.86M$7.29M$7.56M$6.83M$5.78M$5.64M$3.67M$3.42M-
Technology Service$1.21M$1.12M$1.11M$1.10M$957.00K$996.31K$840.97K$786.04K$760.54K$729.55K$688.05K$631.20K$645.73K$609.07K$514.35K$377.13K$324.25K$315.91K--

Joint's latest quarterly revenue breakdown by geography, as of Mar 23: Revenues and Management Fees from Company Clinics (60.20%), Royalty (24.13%), Advertising (6.86%), Technology Service (4.25%), Franchise (2.65%), Product and Service, Other (1.37%), and Regional Developer Fees (0.53%).

Joint Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
DCGODocGo$322.20T$73.42T
LUCDLucid Diagnostics$4.71B$1.47B
BTMDbiote$192.22M$44.23M
CCLDCareCloud$120.50M$31.88M
JYNTJoint$54.90M$15.18M
APYXApyx Medical$52.10M$13.88M
RPIDRapid Micro Biosystems$33.59M$8.05M
SERASera Prognostics$81.00K$30.00K
CGTXCognition Therapeutics--
IKTInhibikase Therapeutics--

JYNT Revenue FAQ


What is Joint’s yearly revenue?

Joint's yearly revenue for 2025 was $54.9M, representing an increase of 5.24% compared to 2024. The company's yearly revenue for 2024 was $52.16M, representing an increase of 11.04% compared to 2023. JYNT's yearly revenue for 2023 was $46.98M, representing a decrease of -53.60% compared to 2022.

What is Joint’s quarterly revenue?

Joint's quarterly revenue for Q2 2026 was $15.18M, a 2.44% increase from the previous quarter (Q1 2026), and a 14.41% increase year-over-year (Q2 2025). The company's quarterly revenue for Q1 2026 was $14.82M, a -2.29% decrease from the previous quarter (Q4 2025), and a 13.33% increase year-over-year (Q1 2025). JYNT's quarterly revenue for Q4 2025 was $15.17M, a 13.35% increase from the previous quarter (Q3 2025), and a 0% increase year-over-year (Q4 2024).

What is Joint’s revenue growth rate?

Joint's revenue growth rate for the last 3 years (2023-2025) was 16.86%, and for the last 5 years (2021-2025) was -31.39%.

What are Joint’s revenue streams?

Joint's revenue streams in c 25 are Royalty, Technology Service, Product and Service, Other, Franchise, and Advertising. Royalty generated $33.2M in revenue, accounting 60.49% of the company's total revenue, up 3.29% year-over-year. Technology Service generated $6.04M in revenue, accounting 11.00% of the company's total revenue, up 6.16% year-over-year. Product and Service, Other generated $1.83M in revenue, accounting 3.34% of the company's total revenue, down -2.91% year-over-year. Franchise generated $3.37M in revenue, accounting 6.14% of the company's total revenue, up 12.46% year-over-year. Advertising generated $10.45M in revenue, accounting 19.04% of the company's total revenue, up 13.84% year-over-year.

What is Joint’s main source of revenue?

For the fiscal year ending Dec 25, the largest source of revenue of Joint was Royalty. This segment made a revenue of $33.2M, representing 60.49% of the company's total revenue.